Treatment of experimental ulcerative colitis
Bull Exp Biol Med. 2012 Oct;153(6):889-92.
doi: 10.1007/s10517-012-1852-z.
[Article in
English,
Russian]
Affiliation
- 1 Institute of Gastroenterology, Moscow, Russia.
Abstract
The effects of infliximab, an anticytokine drug, on the course of inflammatory process was studied on the model of ulcerative colitis induced by injection of picrylsulfonic acid. Infliximab prevented the development of toxic dilatation and a drop of bioelectric activity of smooth muscles via maintenance of activity of the intramural nervous system neurons.
MeSH terms
-
Action Potentials / drug effects
-
Action Potentials / physiology
-
Animals
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Cecum / drug effects*
-
Cecum / pathology
-
Colitis, Ulcerative / chemically induced
-
Colitis, Ulcerative / drug therapy*
-
Colitis, Ulcerative / pathology
-
Colon / drug effects*
-
Colon / pathology
-
Electrodes
-
Gastrointestinal Agents / pharmacology
-
Gastrointestinal Agents / therapeutic use*
-
Ileum / drug effects*
-
Ileum / pathology
-
Infliximab
-
Muscle, Smooth / drug effects*
-
Muscle, Smooth / pathology
-
Rats
-
Rats, Wistar
-
Treatment Outcome
-
Trinitrobenzenesulfonic Acid
Substances
-
Antibodies, Monoclonal
-
Gastrointestinal Agents
-
Trinitrobenzenesulfonic Acid
-
Infliximab